MARKET

ARVN

ARVN

Arvinas
NASDAQ

Real-time Quotes | Nasdaq Last Sale

33.88
-0.27
-0.79%
Closed 16:00 07/02 EDT
OPEN
34.44
PREV CLOSE
34.15
HIGH
34.46
LOW
32.85
VOLUME
287.73K
TURNOVER
--
52 WEEK HIGH
61.57
52 WEEK LOW
15.19
MARKET CAP
1.33B
P/E (TTM)
-15.1717
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ARVN stock price target is 61.50 with a high estimate of 79.00 and a low estimate of 43.00.

EPS

ARVN News

More
Arvinas Appoints Wendy Dixon, Ph.D., to its Board of Directors
NEW HAVEN, Conn., June 29, 2020 -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation,.
GlobeNewswire · 6d ago
Arvinas to Present Virtually at the BMO 2020 Prescriptions for Success Healthcare Conference
NEW HAVEN, Conn., June 17, 2020 -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation,.
GlobeNewswire · 06/17 11:00
Here is What Hedge Funds Think About Arvinas, Inc. (ARVN)
Insider Monkey · 06/15 14:48
Arvinas (ARVN) Investor Presentation - Slideshow
Seeking Alpha - Article · 06/12 20:42
Arvinas Appoints Linda Bain to its Board of Directors
NEW HAVEN, Conn., June 11, 2020 -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation,.
GlobeNewswire · 06/11 11:00
Arvinas, Inc. (ARVN) Upgraded to Buy: Here's Why
Arvinas, Inc. (ARVN) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks · 06/05 16:00
Arvinas to Present Virtually at the Goldman Sachs 41st Annual Global Healthcare Conference
NEW HAVEN, Conn., June 05, 2020 -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation,.
GlobeNewswire · 06/05 11:00
72 Biggest Movers From Friday
Gainers Adaptimmune Therapeutics plc (NASDAQ: ADAP) shares jumped 127.8% to close at $11.07 on Friday after the company announced updated data from its ADP-A2M4 Phase 1 trial at the American Society for Clinical Oncology Annual Meeting.
Benzinga · 06/01 08:53

Industry

Pharmaceuticals
+0.58%
Pharmaceuticals & Medical Research
+0.61%

Hot Stocks

Symbol
Price
%Change

About ARVN

Arvinas, Inc., formerly Arvinas Holding Co LLC, is a development staged biopharmaceutical company. The Company is engaged in the development and commercialization of therapies to degrade disease-causing proteins. The Company uses its technology platform to engineer proteolysis targeting chimeras (PROTACs), which are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The Company is using its PROTAC platform to build an pipeline of protein degradation product candidates to target diseases in a wide range of organ systems and tissues. It is also focused on advancing its lead product candidates, ARV-110 and ARV-471, into Phase 1 clinical trials. It seeks to initiate a Phase 1 clinical trial for ARV-110 in men with metastatic castration-resistant prostate cancer (mCRPC), and a Phase 1 clinical trial for ARV-471 in women with metastatic ER positive, HER2 negative breast cancer, or ER+ breast cancer.
More

Webull offers kinds of Arvinas Inc stock information, including NASDAQ:ARVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARVN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARVN stock methods without spending real money on the virtual paper trading platform.